Wockhardt gets US FDA nod for generic anti-bacterial drug
- North Korea pulled out of Olympic meeting with Mike Pence, says US
- Reliance Jio ranks 17th in Fast Company’s 50 Most Innovative Companies list
- Red flags around Nirav Modi’s diamond empire were raised as early as in 2015
- How Tata group’s changing under N. Chandrasekaran
- Grofers in talks to raise up to $65 million at 40% less valuation
New Delhi: Drug firm Wockhardt has received approval from the US health regulator to market generic version of Wyeth’s Zosyn, used for treating bacterial infections, in the American market.
The application for the product to the US Food and Drug Administration (USFDA) was made by the company’s subsidiary Wockhardt Bio AG, the Mumbai-based company said in a regulatory filing.
“Wockhardt Bio AG had filed this abbreviated new drug application (ANDA) in collaboration with Fresinius Kabi, Italy (FKAI) where the product development was completed,” it added.
The ANDA will be manufactured commercially at FKAI, Mitim, Italy, it said. Wockhardt stock closed 2.54% down at Rs727.60 on BSE.